Deniz Gezer

Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial

Hartmut Goldschmidt, K. Elias, Uta Bertsch et al. · The Lancet Haematology · 2022 · 142 citations

Transplantation-eligible Patients, Hematological Malignancy, Part 1 +9

Hypoxia-inducible factor 1 (HIF-1) is a new therapeutic target in JAK2V617F-positive myeloproliferative neoplasms

Julian Baumeister, Nicolas Chatain, Annika Hubrich et al. · Leukemia · 2019 · 114 citations

Hematological Malignancy, New Therapeutic Target, Hypoxia (Medicine) +8

Real-world analysis of teclistamab in 123 RRMM patients from Germany

Christine Riedhammer, Florian Bassermann, Britta Besemer et al. · Leukemia · 2024 · 87 citations · Full text

Hif-2α is not essential for cell-autonomous hematopoietic stem cell maintenance

Amélie V. Guitart, Chithra Subramani, Alejandro Armesilla-Diaz et al. · Blood · 2013 · 85 citations

Fumarate hydratase is a critical metabolic regulator of hematopoietic stem cell functions

Amélie V. Guitart, Theano I. Panagopoulou, Arnaud Villacreces et al. · The Journal of Experimental Medicine · 2017 · 82 citations · Full text